Nasopharyngeal cancer screening with an anti-BNLF2b antibody: a new arrow in the quiver?

Nature Reviews Clinical Oncology, Published online: 04 October 2023; doi:10.1038/s41571-023-00827-1Epstein–Barr virus (EBV)-based biomarkers are used for nasopharyngeal carcinoma (NPC) screening in endemic regions. A recent prospective study describes the use of a new serological biomarker, antibodies targeting the EBV protein BNLF2b, for NPC screening in>20,000 participants. This biomarker yielded both higher sensitivity and specificity for NPC detection in the screening cohort compared with the conventionally used antibodies. Herein, we highlight the key findings of this study and discuss the implications of these results.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research